Sponsor Dossier
Amdipharm Mercury
Sponsor Dossier for Amdipharm Mercury. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ANDROCUR
- Brand: ANDROCUR-100
- Brand: APRESOLINE
- Brand: COBAL-B12
- Brand: CYCLONEX
- Brand: DIBENYLINE
- Brand: ERYTHROCIN
- Brand: HYGROTON
About
Amdipharm Mercury is an Australian Private Company with ABN 91118106684, registered in NSW and currently active. The company operates under the trading name Mercury Pharma (Australia).
Portfolio
Amdipharm Mercury holds 23 brands on the ARTG, of which 21 are indexable. Twenty brands have Product Information on file, 12 are PBS-listed, 6 have PBAC outcomes on record, and 2 have AusPARs on record. Notable brands include Androcur, Androcur-100, Apresoline, Cobal-B12, Cyclonex, Dibenyline, Erythrocin, Hygroton, Locacorten-Vioform, Mytolac, Neo-Mercazole, and NortriTabs.
Therapeutic focus —
Neurology: 5 brands — Oncology: 5 brands — Cardiology: 2 brands — Haematology: 2 brands — Hepatology: 1 brand — Psychiatry: 1 brand — Urology: 1 brand — Endocrinology: 1 brand — Women's Health: 1 brand — Pain & Anaesthesia: 1 brand — Infectious Disease: 1 brand — Immunology: 1 brand — Dermatology: 1 brand
PBS footprint
Twelve brands in the Amdipharm Mercury portfolio are PBS-listed, with the portfolio last touching the PBS schedule on 2026-05-01.
Regulatory activity
The most recent PBAC outcome for Amdipharm Mercury was recorded on 2024-07-01, with 6 brands holding PBAC outcomes on record. The most recent AusPAR dates to 2013-04-04, with 2 brands holding AusPARs on record.